Key facts: AstraZeneca's Enhertu gains US Breakthrough status; LATIFY trial fails
I'm PortAI, I can summarize articles.
AstraZeneca's Enhertu gained Breakthrough Therapy Designation in the US for HER2-positive early breast cancer, showing promise in reducing disease recurrence after neoadjuvant treatment.12AstraZeneca's Phase III LATIFY trial of Imfinzi and ceralasertib for advanced lung cancer failed to improve survival rates. The stock dropped 0.6% after the announcement.345
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: TradingView The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments